Baltimore Jury Awards Record $1.56 Billion in Johnson and Johnson Talc Mesothelioma Case

A Baltimore jury ordered Johnson and Johnson and its subsidiaries to pay $1.56 billion to a woman who developed peritoneal mesothelioma after decades of using the company’s talc-based baby powder. The December 22, 2025, verdict is the largest single-plaintiff award in the ongoing talc litigation against J&J.

The jury found that J&J failed to warn consumers about asbestos contamination in its talc products and actively concealed the known risks.

The Verdict Breakdown

The $1.56 billion award consists of three components: $1 billion in punitive damages against Johnson and Johnson, $500 million in punitive damages against Pecos River Talc LLC (a J&J subsidiary), and $59.84 million in compensatory damages covering medical costs and pain and suffering.

The case, identified as Craft v. Ahold Delhaize US Inc., was tried in Baltimore. The plaintiff presented evidence that asbestos fibers in J&J’s talc products caused her peritoneal mesothelioma, a cancer of the abdominal lining.

The punitive damages, which account for more than 96% of the total award, reflect the jury’s finding that J&J’s conduct went beyond negligence. Jurors concluded the company knew about asbestos contamination and deliberately chose not to disclose it.

A Pattern of Verdicts

The Baltimore award is part of an accelerating series of talc verdicts against J&J:

• October 2025: A California jury awarded $966 million to a family after a mesothelioma death linked to talc use.
• October 2025: A Florida jury awarded $20 million in a mesothelioma case.
• December 12, 2025: Two women in Los Angeles with ovarian cancer received a combined $40 million verdict.
• February 2026: A Pennsylvania jury awarded $250,000 in an ovarian cancer case where the plaintiff died in 2019 and her children continued the lawsuit.

The pattern spans multiple jurisdictions, cancer types, and jury compositions. In January 2026, a federal judge ruled that plaintiffs’ scientific experts could testify about the link between talc and cancer, clearing a Daubert challenge that could have limited testimony in the more than 67,000 pending federal cases.

J&J’s Response

Johnson and Johnson stated it would appeal the Baltimore verdict. The company maintains that its talc products do not contain asbestos and do not cause cancer, citing studies and pointing to the FDA’s position that talc is not classified as a carcinogen.

J&J has previously attempted to resolve talc litigation through a bankruptcy restructuring strategy, using a subsidiary to absorb liability and file for Chapter 11 protection. That approach, sometimes called the “Texas two-step,” has faced legal challenges and judicial skepticism.

The company continues to defend individual cases at trial while the appeals process plays out.

The Broader Talc Litigation

More than 67,000 talc lawsuits remain pending against J&J in federal and state courts nationwide. The cases involve two primary cancer types: mesothelioma (linked to asbestos fibers in talc) and ovarian cancer (linked to talc application in the genital area).

In 2023, the World Health Organization’s International Agency for Research on Cancer assessed that talc exposure “probably” increases cancer risk, particularly for ovarian cancer. That assessment added scientific weight to claims that had been mounting in courtrooms for years.

J&J discontinued its talc-based baby powder in North America in 2020, switching to a cornstarch formula. The company said the decision was driven by changing consumer preferences, not safety concerns.